Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| (MM) | NASDAQ:TRGT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.9601 | 0 | 01:00:00 |
From Mar 2020 to Mar 2025
Drug maker AstraZeneca PLC (AZN.LN) Wednesday said it intends to start phase IIb studies of AZD3480 in attention deficit hyperactivity disorder, or ADHD.
The company said it has agreed to make a $10 million milestone payment to Targacept Inc. (TRGT).
AstraZeneca said it plans to continue development of AZD1446 for Alzheimer's disease, which is currently in phase one and was discovered in the ongoing AstraZeneca-Targacept research collaboration.
In Alzheimer's disease, development of AZD1446 has been prioritized over further development of AZD3480, AstraZeneca said.
Company Web site: www.astrazeneca.com
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
1 Year Targacept Chart |
1 Month Targacept Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
